Passage Bio, Inc. (PASG)
NCM – Real vaqt narxi. Valyuta: USD
4.59
+0.09 (2.00%)
Yopilishda: Aug 12, 2026, 4:00 PM EDT
4.59
0.00 (0.00%)
Bozordan keyin: Aug 12, 2026, 4:10 PM EDT
Find any stock by ticker or company name

NCM – Real vaqt narxi. Valyuta: USD
4.59
+0.09 (2.00%)
Yopilishda: Aug 12, 2026, 4:00 PM EDT
4.59
0.00 (0.00%)
Bozordan keyin: Aug 12, 2026, 4:10 PM EDT
Passage Bio, Inc., gen terapiyasi kompaniyasi, markaziy asab tizimi kasalliklari uchun gen terapiyasini ishlab chiqadi. U progranulin etishmovchiligidan kelib chiqqan FTDni davolash uchun funktsional granulini (GRN) va progranulin (PGRN) kodlovchi genni PBFT02ni ishlab chiqadi; chaqaloq GM1 uchun β-galaktosidazni kodlovchi funktsional GLB1 genini PBGM01ni; va Krabbe kasalligini davolash uchun PBKR03ni ishlab chiqadi. Kompaniya metakromatik leyko distrofiyasini davolash uchun PBML04ni; amiotrofik lateral sklerozni davolash uchun PBAL05ni; va Huntington kasalligi uchun boshqa dasturlarni ishlab chiqadi. U Pensilvaniya universiteti gen terapiyasi dasturining vasiylari bilan strategik tadqiqot hamkorligiga ega; hamda Catalent Maryland, Inc. bilan hamkorlik shartnomasi va ishlab chiqish xizmatlari va klinik ta'minot shartnomasiga ega. Passage Bio, Inc. 2017 yilda tashkil etilgan va Filadelfiya, Pensilvaniya shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. William Chou M.D., Ph.D. | President, CEO & Director |
| Ms. Kathleen Borthwick | Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-10 | 10-Q | pasg-20260630x10q.htm |
| 2026-07-22 | 425 | ny20077915x2_425.htm |
| 2026-07-21 | S-4 | ny20077915x1_s4.htm |
| 2026-06-24 | 425 | tm2618476d3_425.htm |
| 2026-05-27 | 8-K | pasg-20260521x8k.htm |
| 2026-05-26 | 8-K | tm2615548d1_8k.htm |
| 2026-05-12 | 10-Q | pasg-20260331x10q.htm |
| 2026-04-28 | 8-K | tm2612859d1_8k.htm |
| 2026-04-20 | 8-K | tm2612152d1_8k.htm |
| 2026-04-07 | DEFA14A | pasg-20260407xdefa14a.htm |